Group 1 - The core viewpoint of the news highlights that Tailin Bio's stock closed at 21.03 yuan, down 1.73%, with a rolling PE ratio of 238.08 times, and a total market value of 2.549 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Tailin Bio at the 117th position [1][3] - The net outflow of main funds for Tailin Bio on July 4 was 2.3092 million yuan, with a total outflow of 23.9872 million yuan over the past five days [1] Group 2 - Tailin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control, innovative drug development, and process analysis, serving various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]

证券代码：300813 证券简称：泰林生物 公告编号：2025-054 浙江泰林生物技术股份有限公司 关于取得专利证书及计算机软件著作权登记证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）、浙江泰林分析仪器有限公司（以下简称"泰林分析仪 器"）、浙江泰林医疗器械有限公司（以下简称"泰林医疗器械"）于近期共取得 了 17 项专利证书（其中发明专利 2 项）以及 1 项计算机软件著作权登记证书， 具体情况如下： | 序号 | 软件名称 | 著作权人 | 证书号 | 首次发表日 | 登记日期 | 权利 取得 | 权利 | 登记号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期 | | 方式 | 范围 | | | 1 | 藻类/两 虫智能分 | 泰林生命 | 软著登字第 15744971 | 2024 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：300813 证券简称：泰林生物 公告编号：2025-053 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第七次会议、第四届监事会第七次会议，于 2025 年 5 月 19 日召开 2024 年年度股东大会，审议通过了《关于 2021 年向不特定对象发行可转 换公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流 动资金的议案》《关于拟与杭州富春湾新城管理委员会签订高性能过滤器及配套 功 能 膜 产 业 化 项 目 合 同 书 的 议 案 》， 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于 2021 年向不特定对象发行可转换 公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流动 资金的公告》（公告编号：2025-030）、《关于拟与杭州富春湾新城管理委员会签 订高性能过滤器及配套功能膜产业化项目合同书暨对外投资的公告》（公告编号 ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the procedures and results of Zhejiang Tailin Biotechnology Co., Ltd.'s 2025 Second Extraordinary General Meeting of Shareholders are in compliance with relevant laws and regulations [4][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the proposal to hold the 2025 Second Extraordinary General Meeting by the eighth meeting of the fourth board of directors [5]. - The meeting notice included details such as the time, location, convenor, voting methods, and agenda, ensuring shareholders could attend in person or via proxy [5][6]. - The actual time and location of the meeting matched the notice, and the procedures adhered to the requirements of the Company Law and other relevant regulations [6]. Group 2: Attendance and Voting - A total of 79 participants attended the meeting, representing 68,047,805 shares, which is 56.1454% of the total voting shares [8]. - Among the attendees, 74 were small investors, holding 572,207 shares, accounting for 0.4721% of the total voting shares [8]. - The voting process combined on-site and online methods, with specific time slots for online voting clearly outlined in the meeting notice [6][10]. Group 3: Resolutions and Voting Results - The meeting reviewed and voted on the agenda items as stated in the notice, with the results aligning with the announced agenda [9]. - The voting results showed that 67,957,442 shares were in favor of the resolutions, representing a significant majority of the votes cast [10]. - The resolutions passed were ordinary resolutions, requiring a simple majority for approval, and the results were announced immediately after the voting concluded [10][11].

国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关于 浙江泰林生物技术股份有限公司 2025 年第二次临时股东大会 国浩律师（杭州）事务所 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年六月 国浩律师（杭州）事务所 法律意见书 关 于 浙江泰林生物技术股份有限公司 2025 年第二次临时股东大会 法律意见书 致：浙江泰林生物技术股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江泰林生物技术股份有 限公司（以下简称"公司"）的委托，指派律师出席公司 2025 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300813 证券简称：泰林生物 公告编号：2025-052 特别提示： 1.本次股东大会不涉及否决议案的情形； 浙江泰林生物技术股份有限公司 2.本次股东大会不涉及变更以往股东大会已通过决议的情形。 2025 年第二次临时股东大会决议公告 2.会议出席情况 一、会议召开和出席情况 1.会议召开情况 （1）召开时间：2025年6月30日（星期一）14:00 （2）召开地点：公司会议室（浙江省杭州市滨江区南环路2930号公司12楼 大会议室） （3）召开方式：现场结合网络 （4）召集人：公司董事会 （5）主持人：董事长叶大林先生 （6）本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》及《公司章程》等相关规定。 其中，中小股东（指除公司的董事、监事、高级管理人员以及单独或者合计 持有公司5%以上股份的股东以外的其他股东）表决情况：同意481,844股，占出 席本次股东大会中小股东有效表决权股份总数的84.2080％；反对30,557股，占 出席本次股东大会中小股东有效表决权股份总数的 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-051 统一社会信用代码：91330183MA27X83T5P 浙江泰林生物技术股份有限公司 关于全资子公司变更经营范围并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司全资子公司浙江泰林生命科学有限公司（以 下简称"泰林生命科学"）因业务发展需要，对经营范围进行了变更。近日泰林 生命科学已完成工商变更登记手续并取得了杭州市富阳区市场监督管理局核发 的《营业执照》，相关变更情况如下： 变更事项 变更前 变更后 经营范围 一般项目：技术服务、技术开发、 技术咨询、技术交流、技术转让、 技术推广；仪器仪表制造；仪器仪 表销售；第二类医疗器械销售；工 业酶制剂研发；专用化学产品制造 （不含危险化学品）；专用化学产 品销售（不含危险化学品）；工程 和技术研究和试验发展；塑料制品 制造；塑料制品销售；环境保护专 用设备制造；环境保护专用设备销 售；互联网销售（除销售需要许可 的商品）；日用口罩（非医用）生 产；日用口罩（非医用）销售；母 婴用品制造；母婴用 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-050 浙江泰林生物技术股份有限公司 关于变更注册资本并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）于2025年4月24日召 开第四届董事会第七次会议，于2025年5月19日召开2024年年度股东大会，会议 审议通过了《关于变更注册资本并修订〈公司章程〉的议案》，具体内容详见披 露于巨潮资讯网的《关于变更注册资本并修订〈公司章程〉的公告》（公告编号： 2025-028）。 近日公司完成工商变更登记并取得了浙江省市场监督管理局核发的新营业 执照。具体工商登记信息如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 注册资本 | 壹亿零捌佰陆拾柒万陆仟陆佰陆 | 壹亿贰仟壹佰壹拾玖万玖仟贰 | | | 拾叁元 | 佰壹拾玖元 | 一、本次变更情况 类型：股份有限公司(上市、自然人投资或控股) 法定代表人：叶大林 注册资本：壹亿贰仟壹佰壹拾玖万玖仟贰佰壹拾玖元 成立日期：2002年01月0 ...

关于签订募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江泰林生物技术股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2021〕2258 号）同意 注册，浙江泰林生物技术股份有限公司（以下简称"公司"）向不特定对象发行 2,100,000 张可转换公司债券，每张面值为人民币 100 元，募集资金总额人民币 210,000,000.00 元。扣除各项发行费用后（不含税）的实际募集资金净额为 204,121,111.10 元。募集资金于 2022 年 1 月 4 日划入募集资金专户，天健会计 师事务所（特殊普通合伙）已对公司本次上述募集资金到位情况进行了审验，并 出具了天健验〔2022〕1 号《验资报告》。 证券代码：300813 证券简称：泰林生物 公告编号：2025-049 浙江泰林生物技术股份有限公司 公司于2022年1月18日与杭州银行股份有限公司江城支行以及保荐机构长城 证券股份有限公司签订了《募集资金三方监管协议》，2023年12月21日，公司和 ...